FBLG Company Profile and Key Details

FibroBiologics, Inc. Common Stock (NASDAQ:FBLG) closed at $0.25 USD, losing -$0.01 (-2.82%) from the previous close of $0.26. The stock is currently mid-range between its 52-week high and low $0.23 and $2.51. With a market capitalization of about $10.53 million, FibroBiologics, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.57). Key stats such as the average daily volume over the past year has been around 1.44 million shares, volume is running light vs its 52-week average. Headquartered in Houston, DE, FibroBiologics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter O'Heeron, the company employs approximately 13 people and listed since February 01, 2024. FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States.

FibroBiologics, Inc. Common Stock has 41.89 million shares outstanding. The public float is 32.07 million shares, elevated short interest at 2.90% of float. This equals 1.04 million shares. The short ratio is 2.17 days. Institutional investors hold 15.23% of the float. Insiders own 19.57%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

FibroBiologics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.10. This means the shares are trading above this model’s fair value.

FBLG has shown weak momentum, losing -25.65% over the past week and -51.45% over the past quarter, though year-to-date performance is down -87.08%. Short-term trend indicators are bullishly aligned (SMA20 -8.64%, SMA50 -24.8%, SMA200 -61.08%). The stock’s 14-day RSI is 42.63 (neutral), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.7% below its high and over 9.86% above its low. Average 10-day trading volume of 3.04 million shares is significantly above the 3-month average of 1.39 million, indicating heightened recent market interest.

Wall Street analysts project EPS growth of -9.52% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 18 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $5.00. The high target offers 6053.85% upside. The low target suggests 1823.08% downside. The mean target is $14.28. This offers 5392.31% upside. FibroBiologics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended October 31, 2025, missed forecasts by 30.0%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include -77.78% in August 13, 2024.

FibroBiologics, Inc. Common Stock (NASDAQ:FBLG) shares are down -87.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows FibroBiologics, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.76. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.30, suggesting 5431.91% upside. Our AI forecast model points to short-term weakness (-11.03% over two weeks), a medium-term fall (-88.39% over three months), and a longer-term loss (-72.92% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that FibroBiologics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.03%, with price expected at $0.23 by January 02, 2026, within a range of $0.19 to $0.27 3-Month Outlook: Projected fall of -88.39%, reaching $0.03 by March 19, 2026, with a range of $0.00 to $0.14. 1-Year Outlook: Projected loss of -72.92%, with price at $0.07 by December 18, 2026, within a range of $0.00 to $0.29.

FibroBiologics, Inc. Common Stock trades at a P/E ratio of -0.76, slightly below the S&P 500 average, with a price-to-sales ratio of 19.56 and a price-to-book ratio of 11.61 reflecting a rich premium to book value. The P/FCF stands at -0.71, also above market averages. Compared to sector medians, FibroBiologics, Inc. Common Stock P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.